The Latest Regenerative Medicine Articles from Streetwise Reports


IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

  ()
Shares of IVERIC bio traded 100% higher after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. read more >

Fiscal Year 'Reads Well' for Regenerative Medicine Company

Research Report
  ()
The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. read more >
Showing Results: 1 to 2 of 2

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"DRRX's psoriasis trial is on target for topline data by year-end 2019." ❭
– Ed Arce, H.C. Wainwright & Co.